Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase I/II study of JR-446 in mucopolysaccharidosis type IIIB
jRCT2071240043Phase 2Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Nov 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JR-446 in mucopolysaccharidosis type IIIB, sponsored by JCR Pharmaceuticals. Primary endpoints: Safety and tolerability of JR-446 and Pharmacodynamic effects of JR-446. Started Nov 2024; status: active, not recruiting.
02
Drugs
JR-446
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on jRCT2071240043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240043.